The Latest

  • A stylized illustration of a pill breaking apart into smaller pills.
    Image attribution tooltip
    Brian Tucker / BioPharma Dive/BioPharma Dive
    Image attribution tooltip

    The biopharma industry outlook on 2026: Optimism and tension

    A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.

  • A scientist engaging in labratory work.
    Image attribution tooltip
    Permission granted by Catalent
    Image attribution tooltip
    Sponsored by Catalent

    The crucial role of raw material selection for success in cell therapy manufacturing

     Why raw materials make or break cell therapy manufacturing success.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Startup Formation Bio is paying up to $500 million for a prospect with the same mechanism as AbiVax’s closely watched inflammatory bowel disease drug obefazimod.

    Updated 16 hours ago
  • An infant's left ear is in the foreground of this image, which is otherwise blurred.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Lilly bets on Seamless, delving further into genetic medicine for hearing loss

    The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.

  • A photo of the Westin St. Francis Hotel in San Francisco.
    Image attribution tooltip
    anouchka via Getty Images
    Image attribution tooltip
    Deep Dive

    5 questions facing biopharma in 2026

    The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the renewed optimism will carry over into the new year.

  • A piece of paper with the word "Medicare" emblazoned on a blue background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts

    Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — draw very limited revenue from Medicare, an analyst pointed out.

  • Three laboratory technicians stand over a machine that labels drug vials.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    China’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says

    The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Eikon Therapeutics outlined terms for an IPO that could be worth up to $317 million. Elsewhere, a liver disease-focused spinout of BioVie joined the queue.

    Updated Jan. 28, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Halozyme buys a biotech startup; Cytokinetics launches heart drug

    Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst wrote. Elsewhere, Boehringer dipped into China for a bispecific drug and a trans-Atlantic VC firm restocked.

  • Intellia Therapeutics headquarters in Cambridge, MA
    Image attribution tooltip
    Courtesy of Intellia Therapeutics
    Image attribution tooltip
    Gene editing

    FDA lifts hold on an Intellia CRISPR drug trial

    Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.

  • A headshot of Johnston Erwin, CEO of TRex Bio.
    Image attribution tooltip
    Permission granted by TRex Bio
    Image attribution tooltip

    An immune drug developer raises $50M to finance its eczema drug testing

    TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

  • A Sarepta logo is displayed on a building in Cambridge, Massachusetts on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time

    On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.

  • Engraving on a wall reads "wall street."
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    IPO window

    Biotech investor Cormorant secures $150M for another SPAC deal

    Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.

  • Sanofi
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    Sanofi to seek approval of touted eczema drug despite mixed results

    Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal

    Novo shares have surged more than 20% amid oral Wegovy’s fast start. Elsewhere, Terns opened up room for a potential partnership and Corcept solidified its case for an ovarian cancer drug.

  • The Federal Trade Commission entrance is seen in 2025 in Washington, DC.
    Image attribution tooltip
    Leigh Vogel via Getty Images
    Image attribution tooltip

    Express Scripts considering settlement in FTC insulin price lawsuit

    The antitrust agency paused its lawsuit against the pharmacy benefit manager while the two discuss a proposed consent agreement.

  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    BioMarin vets form Mendra to ‘modernize’ rare disease drug development

    Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use AI to help accelerate their development.

  • The top of the U.S. Capitol Building's dome is pictured on a cloudy day.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Congress eyes tackling healthcare consolidation

    “I think there’s common ground here,” one Republican congressman said Wednesday during a House Budget Committee hearing. Squaring up against healthcare monopolies would be a major pivot for the GOP.

  • A photo of people walking in front of the Westin St. Francis Hotel in San Francisco
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Emerging biotech

    On biotech’s biggest stage, renewed excitement gets a stress test

    A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some aren’t sure if the rebound is here to stay.

  • A bottle of pills lays on top of a sheet of $100 bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Investors load Corxel with $287M for a ‘differentiated’ obesity pill

    The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.

  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    FDA lays out new path to speed development of multiple myeloma drugs

    In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines. 

  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J eyes $100B in sales amid gains for cancer, immune drugs

    Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.

  • BMS corporate sign
    Image attribution tooltip
    Courtesy of BMS
    Image attribution tooltip

    Bristol Myers buys into Janux’s ‘masked’ T cell engagers

    Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote. 

  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Corvus shares nearly triple on positive data for eczema pill

    While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

  • A headshot of Ron Renaud, the CEO of Kailera Therapeutics.
    Image attribution tooltip
    Permission granted by Kailera Therapeutics
    Image attribution tooltip
    Q&A // Emerging biotech

    Kailera’s Ron Renaud on how a China-linked startup can compete in obesity

    In an interview with BioPharma Dive, the veteran biotech CEO said there remains a “significant opportunity” for young companies in a market dominated by Novo Nordisk and Eli Lilly.

  • Professional headshot of Luke Miels
    Image attribution tooltip

    Permission granted by GSK

    Image attribution tooltip

    GSK to buy Rapt in $2.2B deal for food allergy drug

    The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.